Quick Answer
Altimmune, Inc. reported Operating Income Loss of -$94.49 million for the year ending 2025.
- Altimmune, Inc. showed an increase of +8.4% in Operating Income Loss from 2024 to 2025.
- This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: -$1.79 million | Q4 2012: -$1.43 million | Q1 2013: -$1.09 million | Q2 2013: -$1.48 million | Q3 2013: -$3.20 million | Q4 2013: -$5.07 million | Q1 2014: -$2.40 million | Q2 2014: -$1.17 million | Q3 2014: -$4.00 million | Q4 2014: -$2.62 million | Q1 2015: $1.16 million | Q2 2015: -$1.96 million | Q3 2015: -$1.66 million | Q4 2015: -$940.5 thousand | Q1 2016: -$1.25 million | Q2 2016: -$1.60 million | Q3 2016: -$4.79 million | Q4 2016: -$5.51 million | Q1 2017: -$4.52 million | Q2 2017: -$4.01 million | Q3 2017: -$30.95 million | Q1 2018: -$5.99 million | Q2 2018: -$5.44 million | Q3 2018: -$4.06 million | Q1 2019: -$2.33 million | Q2 2019: -$3.55 million | Q3 2019: -$11.27 million | Q1 2020: -$7.31 million | Q2 2020: -$18.42 million | Q3 2020: -$18.32 million | Q1 2021: -$14.86 million | Q2 2021: -$24.86 million | Q3 2021: -$33.20 million | Q1 2022: -$19.50 million | Q2 2022: -$20.40 million | Q3 2022: -$24.75 million | Q1 2023: -$21.76 million | Q2 2023: -$18.01 million | Q3 2023: -$22.54 million | Q1 2024: -$26.79 million | Q2 2024: -$26.75 million | Q3 2024: -$24.77 million | Q1 2025: -$21.82 million | Q2 2025: -$22.92 million | Q3 2025: -$20.86 million.
- Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Operating Income Loss has declined by 301.2%.
- Historical annual values: Fiscal year 2025: -$94.49 million | Fiscal year 2024: -$103.17 million | Fiscal year 2023: -$95.93 million | Fiscal year 2022: -$87.74 million | Fiscal year 2021: -$96.91 million | Fiscal year 2020: -$54.80 million | Fiscal year 2019: -$21.46 million | Fiscal year 2018: -$42.83 million | Fiscal year 2017: -$52.05 million | Fiscal year 2016: -$11.09 million | Fiscal year 2015: -$3.40 million | Fiscal year 2014: -$10.19 million | Fiscal year 2013: -$10.84 million | Fiscal year 2012: -$6.27 million | Fiscal year 2011: -$11.73 million | Fiscal year 2010: -$23.55 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: